FIELD: medicine.
SUBSTANCE: group of inventions refers to therapeutic agents for bile duct cancer. Therapeutic agent for bile duct cancer contains 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or its pharmaceutically acceptable salt. Also disclosed is a pharmaceutical composition for treating bile duct cancer, comprising said substance, a method of treating bile duct cancer, comprising administering to said patient a substance, as well as use of said substance to produce a therapeutic agent for bile duct cancer.
EFFECT: group of inventions provides effective treatment of bile duct cancer.
10 cl, 7 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT FOR TREATING BREAST CANCER | 2016 |
|
RU2730503C2 |
| THERAPEUTIC AGENT FOR TREATMENT OF HEPATOCELLULAR CARCINOMA | 2019 |
|
RU2777535C2 |
| SALT OF MONOCYCLIC DERIVATIVE OF PYRIDINE AND CRYSTAL THEREOF | 2015 |
|
RU2658821C1 |
| MONOCYCLIC PYRIDINE DERIVATIVE | 2014 |
|
RU2645352C2 |
| COMBINATION OF INHIBITOR FGFR AND INHIBITOR IGF1R | 2015 |
|
RU2715893C2 |
| DRUG AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | 2017 |
|
RU2777595C2 |
| COMBINATIONS | 2015 |
|
RU2715236C2 |
| NEW COMPOUNDS | 2016 |
|
RU2747645C2 |
| COMBINATION OF FGFR4 INHIBITORS AND BILE ACID SEQUESTRANTS | 2017 |
|
RU2742033C2 |
| COMPOUNDS BASED ON PYRAZOLOPYRIDINONE | 2018 |
|
RU2806625C2 |
